Direkt zum Inhalt
Merck

Abnormal retinal development associated with FRMD7 mutations.

Human molecular genetics (2014-04-02)
Mervyn G Thomas, Moira Crosier, Susan Lindsay, Anil Kumar, Masasuke Araki, Bart P Leroy, Rebecca J McLean, Viral Sheth, Gail Maconachie, Shery Thomas, Anthony T Moore, Irene Gottlob
ZUSAMMENFASSUNG

Idiopathic infantile nystagmus (IIN) is a genetically heterogeneous disorder, often associated with FRMD7 mutations. As the appearance of the retina is reported to be normal based on conventional fundus photography, IIN is postulated to arise from abnormal cortical development. To determine whether the afferent visual system is involved in FRMD7 mutations, we performed in situ hybridization studies in human embryonic and fetal stages (35 days post-ovulation to 9 weeks post-conception). We show a dynamic retinal expression pattern of FRMD7 during development. We observe expression within the outer neuroblastic layer, then in the inner neuroblastic layer and at 9 weeks post-conception a bilaminar expression pattern. Expression was also noted within the developing optic stalk and optic disk. We identified a large cohort of IIN patients (n = 100), and performed sequence analysis which revealed 45 patients with FRMD7 mutations. Patients with FRMD7 mutations underwent detailed retinal imaging studies using ultrahigh-resolution optical coherence tomography. The tomograms were compared with a control cohort (n = 60). The foveal pit was significantly shallower in FRMD7 patients (P < 0.0001). The optic nerve head morphology was abnormal with significantly decreased optic disk area, retinal nerve fiber layer thickness, cup area and cup depth in FRMD7 patients (P < 0.0001). This study shows for the first time that abnormal afferent system development is associated with FRMD7 mutations and could be an important etiological factor in the development of nystagmus.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Natriumchlorid, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
Triethanolamin, ≥99.0% (GC)
Sigma-Aldrich
Natriumchlorid -Lösung, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
Natriumchlorid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
Natriumchlorid -Lösung, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
SAFC
Natriumchlorid -Lösung, 5 M
Sigma-Aldrich
Natriumchlorid -Lösung, BioUltra, for molecular biology, ~5 M in H2O
Sigma-Aldrich
Natriumchlorid, 99.999% trace metals basis
Sigma-Aldrich
Natriumchlorid, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
Essigsäureanhydrid, 99.5%
Sigma-Aldrich
Essigsäureanhydrid, ReagentPlus®, ≥99%
Sigma-Aldrich
Natriumchlorid, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
Triethanolamin, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Natriumchlorid, BioPerformance Certified, ≥99% (titration), suitable for insect cell culture, suitable for plant cell culture
Sigma-Aldrich
Natriumchlorid, AnhydroBeads, −10 mesh, 99.999% trace metals basis
Sigma-Aldrich
Essigsäureanhydrid, ACS reagent, ≥98.0%
Sigma-Aldrich
Natriumchlorid-35Cl, 99 atom % 35Cl
Sigma-Aldrich
Triethanolamin, reagent grade, 98%
Sigma-Aldrich
Natriumchlorid, meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%
Sigma-Aldrich
Natriumchlorid -Lösung, 5 M
Sigma-Aldrich
Natriumchlorid, random crystals, optical grade, 99.9% trace metals basis
Sigma-Aldrich
Essigsäureanhydrid, Arxada quality, ≥99.5% (GC)
Sigma-Aldrich
Natriumchlorid -Lösung, 0.85%
Supelco
Natriumchlorid, reference material for titrimetry, certified by BAM, >99.5%
Supelco
Natriumchlorid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Triethanolamin, puriss. p.a., ≥99% (GC)
Sigma-Aldrich
Triethanolamin, puriss., meets analytical specification of NF, ≥99% (GC)
Sigma-Aldrich
Natriumchlorid, tablet
Sigma-Aldrich
Natriumchlorid, tested according to Ph. Eur.
Supelco
Essigsäureanhydrid, for GC derivatization, LiChropur, ≥99.0%